Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 67 of 95, showing 5 Applications out of 471 total, starting on record 331, ending on 335

# Protocol No Study Title Investigator(s) & Site(s)

331.

ECCT/16/11/05   RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
    A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo.   
Principal Investigator(s)
1. Fredrick Kipyego Sawe
Site(s) in Kenya
1. KEMRI/WRP Kericho (Kericho county)
2. KEMRI/WRP Kombewa, Kisumu (Kisumu county)
 
View

332.

ECCT/16/11/04   RV456
    A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo   
Principal Investigator(s)
1. JANET OYIEKO
Site(s) in Kenya
KOMBEWA CLINICAL RESEARCH CENTRE
 
View

333.

ECCT/16/11/03   COAST
    Childrens Oxygen Administration Strategies Trial   
Principal Investigator(s)
1. Kathryn Maitland
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast Provincial General Hospital (Mombasa county)
 
View

334.

ECCT/16/11/02   IMPAACT P1093
    Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents   
Principal Investigator(s)
1. Lucy Koech
Site(s) in Kenya
KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME
 
View

335.

ECCT/16/10/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Professor Walter Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Research (Nairobi City county)
2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
 
View